{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:17:30Z","timestamp":1791307050680,"version":"4.3.1"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,1,1]]},"abstract":"<jats:p> PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity and the overall response rates (RR) and complete response (CR) rates to rituximab (chimeric anti-CD20 monoclonal antibody). <\/jats:p><jats:p> PATIENTS AND METHODS: Between January 1997 and January 1998, 131 patients with newly diagnosed MCL (MCL1; n = 34) and previously treated MCL (MCL2; n = 40), IMC (n = 28), and SLL (n = 29) received rituximab 375 mg\/m<jats:sup>2<\/jats:sup>\/wk for 4 weeks via intravenous infusion. Restaging studies were performed 1 and 2 months after treatment. An analysis of the duration of response was conducted in December 1998. <\/jats:p><jats:p> RESULTS: Eleven patients were unassessable, including one who died of splenic rupture after the first infusion. The RR among the 120 assessable patients was 30% (36 of 120 patients). The RR by histology was as follows: MCL1, 38%; MCL2, 37%; IMC, 28%; and SLL, 14%. Ten patients, all with MCL, achieved CR. The median duration of response in MCL was 1.2 years. Immediate side effects were common and usually responded to adjustments in the infusion rate. There were 31 episodes of infection after treatment; most cases were mild. Cardiac arrhythmia and ophthalmologic side effects occurred in 10 and nine patients, respectively, including one case of severe loss of visual acuity. <\/jats:p><jats:p> CONCLUSION: Single-agent rituximab has moderate activity in MCL and IMC but only limited activity in SLL. The duration of response in MCL was similar to that previously reported in follicular lymphoma. Its use in combination with cytotoxic chemotherapy to increase the CR rate is warranted in MCL and IMC. <\/jats:p>","DOI":"10.1200\/jco.2000.18.2.317","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:32:46Z","timestamp":1487928766000},"page":"317-317","source":"Crossref","is-referenced-by-count":384,"title":["European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma"],"prefix":"10.1200","volume":"18","author":[{"given":"James M.","family":"Foran","sequence":"first","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama Z. S.","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan A.","family":"Popescu","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal-Celigny","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reyes","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Radford","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Bessell","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Souleau","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Benzohra","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"From the Imperial Cancer Research Fund Medical Oncology UnitSt Bartholomew\u2019s Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton; Imperial Cancer Research Fund Cancer Medicine Unit, St. James\u2019 University Hospital, Leeds; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester; and Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom; Centre Jean Bernard, Le Mans; Department of Hematology, Centre Hospitalier Lyon Sud,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0040","unstructured":"Ehrlich  P:  On immunity with special reference to cell life.  Proc R Soc Lond [Biol] 66:424,1990-448,"},{"key":"R2-0040","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"R3-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.4.863.863"},{"key":"R4-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"R5-0040","doi-asserted-by":"publisher","DOI":"10.1038\/332323a0"},{"key":"R7-0040","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"R8-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1644"},{"key":"R9-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"R10-0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"R11-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"R12-0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R13-0040","doi-asserted-by":"crossref","unstructured":"Stansfeld  AG,  Diebold  J,  Noel  H, et al:  Updated Kiel classification for lymphomas.  Lancet 1:292,1988-293,   (letter)","DOI":"10.1016\/S0140-6736(88)90367-4"},{"key":"R14-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R15-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R16-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1452.1452"},{"key":"R17-0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.2829.2829"},{"key":"R18-0040","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900020306"},{"key":"R19-0040","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R20-0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2847"},{"key":"R21-0040","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070103"},{"key":"R23-0040","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R24-0040","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"R25-0040","unstructured":"Hiddemann  W,  Brittinger  G,  Tiemann  M, et al:  Clinical characteristics and response to chemotherapy of mantle cell lymphomas:  Results of a European survey. Proc Am Soc Hematol 88:674a,1996  (abstr)"},{"key":"R26-0040","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059156"},{"key":"R27-0040","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278605751"},{"key":"R28-0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"R29-0040","unstructured":"Coiffier  B,  Haioun  C,  Ketterer  N, et al:  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:  A multicentre phase II study. Blood 92:1927,1998-1932,"},{"key":"R30-0040","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"R31-0040","doi-asserted-by":"crossref","unstructured":"Molica  S,  Levato  D,  Dattilo  A, et al:  Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins.  Eur J Hematol 60:47,1998-52,","DOI":"10.1111\/j.1600-0609.1998.tb00995.x"},{"key":"R32-0040","unstructured":"Piro  L,  White  CA,  Grillo-Lopez  AJ, et al:  Rituxan (rituximab; IDEC-C2B8):  Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin\u2019s lymphoma. Proc Am Soc Hematol 90:510a,1997  (abstr)  (suppl 1)"},{"key":"R33-0040","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050252"},{"key":"R34-0040","doi-asserted-by":"crossref","unstructured":"Winkler  U,  Jensen  M,  Manzke  O, et al:  Severe side effects in patients with B-cell chronic lymphocytic leukemia and leukocytosis treated with the monoclonal anti-CD20 antibody rituximab.  Proc Am Soc Hematol 92:285b,1998   (abstr)  (suppl 1)","DOI":"10.1007\/s002770050419"},{"key":"R35-0040","unstructured":"Nguyen  D,  Amess  J,  Doughty  H, et al:  IDEC-C2B8 anti-CD20 immunotherapy in patients with non-Hodgkin\u2019s lymphoma: Hematological effects in the bone marrow and peripheral blood.  Proc Am Soc Hematol 90:511a,1997   (abstr)  (suppl 1)"},{"key":"R36-0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.2.317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:03:29Z","timestamp":1653516209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.2.317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,1,1]]}},"alternative-id":["10.1200\/JCO.2000.18.2.317"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.2.317","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1,1]]}}}